INCYTE CORP (INCY) Stock News
NASDAQ:INCY - Nasdaq - US45337C1027 - Common Stock - Currency: USD
INCY Latest News, Press Relases and Analysis
What's going on in today's session: S&P500 movers
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Tuesday.
These S&P500 stocks that are showing activity before the opening bell on Thursday.
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.
3 Mid-Cap Stocks with Questionable Fundamentals
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
Mentions: SCI
Incyte Gets FDA Approval for Zynyz in New Cancer Indication
The FDA approves INCY's Zynyz both as monotherapy and in combination with chemotherapy for treating advanced anal cancer.
Incyte Corporation (INCY): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying
We recently published a list of 15 Small-Cap Healthcare Stocks Hedge Funds Are Buying. In this article, we are going to take a look at where Incyte Corporation (NASDAQ:INCY) stands against other small-cap healthcare stocks hedge funds are buying. The U.S. healthcare sector has performed better in 2025 compared to the broader market. After two […]
Mentions: BLK
INCY Q1 Earnings Call: New Product Launches and Pipeline Progress Drive Outperformance
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 19.5% year on year to $1.05 billion. Its non-GAAP profit of $1.16 per share was 10.6% above analysts’ consensus estimates.
INCYTE CORP (NASDAQ:INCY), an undervalued stock with good fundamentals.
INCYTE CORP may be an undervalued stock option. NASDAQ:INCY retains a strong financial foundation and an attractive price tag.
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Incyte to Present at Upcoming Investor Conference
Stocks Surge And Bond Yields Fall For 6th Day, Oil Prices Drop To $60: What's Driving Markets Tuesday?
Wall Street modestly up as investors await economic data and corporate earnings. Bond market continues rally, gold and oil prices fall.Wall Street rises modestly, bond market continues rally, gold and oil prices fall as investors await economic data and corporate earnings.
INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales
Incyte reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.
Here's What Key Metrics Tell Us About Incyte (INCY) Q1 Earnings
The headline numbers for Incyte (INCY) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
NICE Lowered Revenue Outlook But Bullish Analyst Sees AI Momentum And Strong Cash Flow
Rosenblatt analyst Catharine Trebnick maintained NICE Ltd (NASDAQ:NICE) with a Buy rating and lowered the price forecast from $200 to $180 Thursday. Trebnick lowered her price forecast due to reduced fiscal 2025 and 2026 revenue estimates, citing macroeconomic uncertainty, which could further delay multinational Contact Center as a Service (CCaaS) deployments. The price target reflects ~3.4 times (from ~4 times) on the analyst’s revenue estimate of 7% Y/ Y in fiscal 2026. Also Read: Five9 Leans
Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?
Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: BPMC
Blueprint Medicines Corporation (BPMC): Among Takeover Rumors Hedge Funds Are Buying
We recently published a list of 20 Takeover Rumors Hedge Funds Are Buying. In this article, we are going to take a look at where Blueprint Medicines Corporation (NASDAQ:BPMC) stands against other takeover rumor stocks hedge funds are buying. Hedge funds tend to pile up on a stock that gains or is expected to gain […]
Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
